Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects?

× No keyword cloud information.

26 in total

1. [Therapy options of advanced laryngeal carcinomas with regard to the quality of life of the patients].

Authors: Elke Hayn; Martin Burian; Johannes Gobertus Meran
Journal: Wien Med Wochenschr Date: 2006-05

2. Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx.

Authors: Valentina Krstevska; Simonida Crvenkova
Journal: Croat Med J Date: 2006-02 Impact factor: 1.351

Review 3. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.

Authors: Petr Szturz; Kristien Wouters; Naomi Kiyota; Makoto Tahara; Kumar Prabhash; Vanita Noronha; Ana Castro; Lisa Licitra; David Adelstein; Jan B Vermorken
Journal: Oncologist Date: 2017-05-22

4. Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapy.

Authors: Kenji Nakano; Yasuyoshi Sato; Takashi Toshiyasu; Yukiko Sato; Lina Inagaki; Junichi Tomomatsu; Toru Sasaki; Wataru Shimbashi; Hirofumi Fukushima; Hiroyuki Yonekawa; Hiroki Mitani; Kazuyoshi Kawabata; Shunji Takahashi
Journal: Mol Clin Oncol Date: 2015-11-25

5. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.

Authors: Steven F Powell; Kathryn A Gold; Mark M Gitau; Christopher J Sumey; Michele M Lohr; Steven C McGraw; Ryan K Nowak; Ashley W Jensen; Miran J Blanchard; Christopher D Fischer; Julie Bykowski; Christie A Ellison; Lora J Black; Paul A Thompson; Juan L Callejas-Valera; John H Lee; Ezra E W Cohen; William C Spanos
Journal: J Clin Oncol Date: 2020-06-01 Impact factor: 44.544

Review 6. The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?

Authors: Lindsay Carlsson; Scott V Bratman; Lillian L Siu; Anna Spreafico
Journal: Curr Treat Options Oncol Date: 2017-07

Review 7. Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology.

Authors: D Alterio; M Cossu Rocca; W Russell-Edu; S Dicuonzo; G Fanetti; G Marvaso; L Preda; S Zorzi; E Verri; F Nole'; B A Jereczek-Fossa
Journal: Med Oncol Date: 2017-04-08 Impact factor: 3.064

8. Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial.

Authors: Hao Peng; Lei Chen; Yuan Zhang; Wen-Fei Li; Yan-Ping Mao; Fan Zhang; Rui Guo; Li-Zhi Liu; Ai-Hua Lin; Ying Sun; Jun Ma
Journal: Oncologist Date: 2016-08-05

9. Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of cisplatin?

Authors: Mihály Patyánik; Csaba Nemeskéri; Zsuzsa Póti; Dániel Sinkó; Csilla Pesznyák; Réka Király; Róbert Kois; Arpád Mayer
Journal: Strahlenther Onkol Date: 2009-09-12 Impact factor: 3.621

10. Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.

Authors: Musaddiq J Awan; Haley Gittleman; Jill Barnholtz-Sloan; Mitchell Machtay; Phuc Felix Nguyen-Tan; David I Rosenthal; Christopher Schultz; Bradley J Huth; Wade L Thorstad; Steven J Frank; Harold Kim; Robert L Foote; Miriam N Lango; George Shenouda; Mohan Suntharalingam; Jonathan Harris; Qiang Zhang; Quynh-Thu Le; Min Yao
Journal: Oral Oncol Date: 2021-02-25 Impact factor: 5.337